Hospital

Chimeric antigen receptor T-cell therapies were associated with higher incidences, grades of severity, and longer duration of cytokine release syndrome compared with bispecific antibodies.

In a phase 1/2 clinical trial, lisocabtagene maraleucel helped patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) achieve complete response rates.

Compared to placebo, risankizumab significantly reduced symptom severity for patients with moderate to severe disease.

The drug is the first FDA-approved agent for treating hepatorenal syndrome.

Amina Abubakar, PharmD, AAHIVP, discussed her work throughout Africa and particularly in Kenya.

The platform is a first-of-its-kind therapeutic approach to promote remyelination among individuals with relapsing/remitting multiple sclerosis.

Results from the phase 3 RATIONALE 302 trial showed tislelizumab-jsgr prolonged survival compared to chemotherapy in patients who received prior systemic treatment.

The accelerated approval of resmetirom, a once-daily, oral thyroid hormone receptor-β agonist, is the first treatment available for patients with this disease.

This finding was evident in both examined groups and regardless of the patients' B-cell maturation antigen-directed therapy status.

The tool consolidates and highlights key features that would be considered when choosing a biosimilar adalimumab.

At 4 months, 75% of participants achieved remission and no longer showed signs of depression symptoms in a phase 2 clinical trial.

Study results indicate early swap to oral antibiotics in Staphylococcus aureus bacteremia is just as effective.

Furthermore, the study authors indicated that patients with lymphoma and community-acquired pneumonia have broader dysregulated responses.

Aspirin, known as acetylsalicylic acid, has been marketed in ways that have de-emphasized potential risks to children.

This treatment improved the severity of symptoms in patients with scalp and nail psoriasis.

Findings originate from phase 3 data that was recently presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting.

The combination of GZ17-6.02 and bortezomib reduced of HDAC, and as a result ATG13 phosphorylation was enhanced, BAK levels increased, and BCL-XL levels were reduced.

The cream significantly reduced abscesses and inflammatory nodules, reaffirming its efficacy as a maintenance option for HS.

Tacrolimus is a selective calcineurin inhibitor that exerts inhibitory effects on T-cell proliferation.

Although newly approved, there is some debate regarding the benefits and populations in which sotagliflozin will be the most effective.

Pharmacogenomic information can be used to more selectively choose medications and doses that are more appropriate for each individual.

The early phase clinical trial, which ended prematurely in 2013 due to funding challenges, further illustrates disparities in health equity in clinical research.

This initiative aims to raise worldwide awareness of the disease while trying to strengthen the connection between members of the multiple myeloma community.

If clinical trials continue to show that psychedelics offer safe and long-lasting results, then psychedelic-assisted therapy could flourish as a treatment in the mental health space.

Secukinumab affects levels of inflammatory biomarkers, and monitoring levels can help investigators understand how patients are responding to treatment.

GBS can cause transcriptional adaptations, which may increase risk of poor neonate outcomes.

The IVIG therapies were previously approved for 4-week room temperature storage conditions of 25º Celsius during the first 24 months of shelf life.

The study results also indicated that graft versus host disease status was associated with non-compliance following bone marrow transplantation.

In addition, the length of hospital admissions were greater in patients with hidradenitis suppurativa-associated cutaneous squamous cell carcinoma compared to other admissions.

Semaglutide (Wegovy; Novo Nordisk) reduces the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease and either obesity or overweight when combined with the standard-of-care.